BioNovoGen

bionovogen.com

BioNovoGen will be positioned to be one of the key market leaders in developing and commercializing the highest quality biosimilar drugs. We strive to provide the highest quality therapeutics to help bring best in class biologic products to meet patients' needs at affordable prices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

news image

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More

Cell and Gene Therapy, MedTech

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

news image

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More

MedTech

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

news image

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More
news image

Industrial Impact

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More
news image

Cell and Gene Therapy, MedTech

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More
news image

Industry Outlook

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More
news image

MedTech

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us